XLV240726P139500
- 0.00
- 0.000.00%
The Health Care Select Sector SPDR® Fund Newsroom
Piper Sandler Sticks to Its Buy Rating for AbbVie (ABBV)
Piper Sandler Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $344
Johnson & Johnson Analyst Ratings
Daiwa Downgrades Johnson & Johnson to Neutral From Outperform, Adjusts Price Target to $150 From $160
Truist Financial Sticks to Its Buy Rating for Intuitive Surgical (ISRG)
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
Barclays Adjusts Price Target on Intuitive Surgical to $510 From $490
Guggenheim Adjusts Johnson & Johnson's Price Target to $156 From $160, Maintains Neutral Rating
Merck & Co. Poised for Growth: Strong Q2 Performance and Promising Pipeline Fuel Buy Rating
Buy Rating on UnitedHealth Group: Proactive Management and Strong Growth Outlook
Analysts' Top Healthcare Picks: 4D Molecular Therapeutics (FDMT), Intuitive Surgical (ISRG)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Elevance Health (ELV), CVS Health (CVS) and Abbott Laboratories (ABT)
Outperform Rating Reaffirmed for Intuitive Surgical on Strong Q2 2024 Performance and Da Vinci 5 Launch Success
Buy Rating Affirmed for Johnson & Johnson on Strong Growth and Strategic Acquisitions
Johnson & Johnson Analyst Ratings
AbbVie Analyst Ratings
BMO Capital Adjusts Price Target on Merck to $150 From $148
Morgan Stanley Keeps Their Hold Rating on Abbott Laboratories (ABT)
HSBC Adjusts Price Target on Johnson & Johnson to $174 From $170, Maintains Buy Rating
Jefferies Adjusts Price Target on Amgen to $380 From $375